9802416-9

RMP's copy

PCT WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6: C07D 401/04, 405/14, 401/14, 413/14, 471/14, 417/14, 409/14, 471/04 — A1

(11) International Publication Number: WO 97/16440

(43) International Publication Date: 9 May 1997 (09.05.97)

(21) International Application Number: PCT/EP96/04660

(22) International Filing Date: 25 October 1996 (25.10.96)

(30) Priority Data:
95202929.6 30 October 1995 (30.10.95) EP

(34) Countries for which the regional or international application was filed: DE et al.

(71) Applicant (for all designated States except US): JANSSEN PHARMACEUTICA N.V. [BE/BE]; Turnhoutseweg 30, B-2340 Beerse (BE).

(72) Inventors; and

(75) Inventors/Applicants (for US only): JANSSENS, Frans, Eduard [BE/BE]; Tinstraat 79, B-2820 Bonheiden (BE). SOMMEN, François, Maria [BE/BE]; Langenberg 49, B-2323 Wortel (BE). SURLERAUX, Dominique, Louis, Nestor, Ghislaine [BE/BE]; Diegemstraat 48, B-1830 Machelen (BE). LEENAERTS, Joseph, Elisabeth [BE/BE]; Potbergstraat 35, B-2310 Rijkevorsel (BE). VAN ROOSBROECK, Yves, Emiel, Maria [BE/BE]; Zonderschotsesteenweg 26, B-2220 Heist-op den-Berg (BE).


(74) Agent: DE CORTE, Filip; Janssen Pharmaceutica N.V., Patent Dept., Turnhoutseweg 30, B-2340 Beerse (BE).

(81) Designated States: AL, AM, AU, BA, BB, BG, BR, CA, CN, CU, CZ, EE, GE, HU, IL, IS, JP, KG, KR, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, TR, TT, UA, US, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).

Published

With international search report.

(54) Title: 1-(1,2-DISUBSTITUTED PIPERIDINYL)-4-SUBSTITUTED PIPERAZINE DERIVATIVES



(I)

(57) Abstract

This invention concerns the compounds of formula (I), the *N*-oxide forms, the pharmaceutically acceptable addition salts and the stereoisomeric forms thereof, wherein n is 0, 1 or 2; m is 1 or 2, provided that if m is 2, then n is 1; p is 1 or 2; =Q is =O or =NR^3; X is a covalent bond or a bivalent radical of formula -O-, -S-, -NR^3-; R^1 is Ar^1, Ar^1C_{1-6}alkyl or di(Ar^1)C_{1-6}alkyl, wherein each C_{1-6}alkyl group is optionally substituted with hydroxy, C_{1-4}alkyloxy, oxo or a ketalized oxo substituent; R^2 is Ar^2, Ar^2C_{1-6}alkyl, Het^1 or Het^1C_{1-6}alkyl; R^3 is hydrogen or C_{1-6}alkyl; L is hydrogen; Ar^3; C_{1-6}alkyl; C_{1-6}alkyl substituted with 1 or 2 substituents selected from hydroxy, C_{1-6}alkyloxy, Ar^3, Ar^3C_{1-6}alkyloxy and Het^2; C_{3-6}alkenyl; Ar^3C_{3-6}alkenyl; di(Ar^3)C_{3-6}alkenyl or a radical of formula (a-1), (a-2), (a-3), (a-4) or (a-5); Ar^1, Ar^2 and Ar^3 are each phenyl or substituted phenyl; Het^1 and Het^2 are each monocyclic or a bicyclic heterocycle; as substance-P antagonists; their preparation, compositions containing them and their use as a medicine.